Medtronic income statement

In fiscal 2026, Medtronic reported revenue of $36.36bn, up 8.4% on the year before, operating income of $6.47bn (a 17.8% margin) and net income of $4.80bn, or $3.73 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Medtronic: income statement, annual
Fiscal year	2013Apr 2013	2014Apr 2014	2015Apr 2015	2016Apr 2016	2017Apr 2017	2018Apr 2018	2019Apr 2019	2020Apr 2020	2021Apr 2021	2022Apr 2022	2023Apr 2023	2024Apr 2024	2025Apr 2025	2026Apr 2026	LTMJul 2026
Revenue	16.6	17.0	20.3	28.8	29.7	30.0	30.6	28.9	30.1	31.7	31.2	32.4	33.5	36.4	37.5
Cost of revenue	4.1	4.3	6.3	9.1	9.3	9.1	9.2	9.4	10.5	10.1	10.7	11.2	11.6	12.7	13.1
Gross profit	12.5	12.7	14.0	19.7	20.4	20.9	21.4	19.5	19.6	21.5	20.5	21.1	21.9	23.6	24.4
Research and development	1.6	1.5	1.6	2.2	2.2	2.3	2.3	2.3	2.5	2.7	2.7	2.7	2.7	2.9	2.9
Selling, general and administrative	5.7	5.8	6.9	9.5	10.0	10.2	10.4	10.1	10.1	10.3	10.4	10.7	10.8	11.8	12.2
Operating income	4.4	3.8	3.8	5.4	5.4	6.6	6.3	4.8	4.5	5.8	5.5	5.1	6.0	6.5	6.8
Interest expense	0.4	0.4	0.7	1.4	1.1	1.1	1.4	1.1	0.9	0.6	0.6	0.7	0.7	0.7	0.7
Net interest income	—	—	—	—	—	—	—	—	—	0.2	0.4	0.6	0.5	0.4	0.4
Income before tax	4.3	3.7	3.5	4.3	4.6	5.7	5.2	4.1	3.9	5.5	5.4	4.8	5.6	6.1	6.6
Income tax	0.8	0.6	0.8	0.8	0.6	2.6	0.5	−0.8	0.3	0.5	1.6	1.1	0.9	1.3	1.3
Net income	3.5	3.1	2.7	3.5	4.0	3.1	4.6	4.8	3.6	5.0	3.8	3.7	4.7	4.8	5.2
Diluted EPS	$3.37	$3.02	$2.41	$2.48	$2.89	$2.27	$3.41	$3.54	$2.66	$3.73	$2.82	$2.76	$3.61	$3.73	$4.06
Diluted shares (average)	1,028m	1,014m	1,109m	1,426m	1,391m	1,368m	1,358m	1,351m	1,354m	1,351m	1,333m	1,330m	1,290m	1,288m	1,288m
EBITDA	5.2	4.7	5.1	8.2	8.3	9.3	8.9	7.5	7.2	8.5	8.2	7.8	8.8	9.4	8.8

US$ millions unless shown otherwise. Fiscal quarters.

Medtronic: income statement, quarterly
Quarter	2025 Q2Oct 2024	2025 Q3Jan 2025	2025 Q4Apr 2025	2026 Q1Jul 2025	2026 Q2Oct 2025	2026 Q3Jan 2026	2026 Q4Apr 2026	2027 Q1Jul 2026
Revenue	8,403	8,292	8,927	8,578	8,961	9,017	9,807	9,756
Cost of revenue	2,946	2,779	3,147	3,001	3,061	3,261	3,398	3,416
Gross profit	5,457	5,513	5,780	5,577	5,900	5,756	6,409	6,340
Research and development	697	675	684	726	754	722	671	771
Selling, general and administrative	2,757	2,717	2,720	2,806	2,965	2,956	3,057	3,198
Operating income	1,595	1,646	1,436	1,445	1,686	1,464	1,873	1,764
Interest expense	209	179	174	176	181	181	176	186
Net interest income	137	114	147	120	89	85	89	102
Income before tax	1,559	1,540	1,261	1,302	1,597	1,404	1,834	1,769
Income tax	281	237	199	255	215	254	575	289
Net income	1,270	1,294	1,056	1,040	1,374	1,143	1,244	1,470
Diluted EPS	$0.99	$1.01	$0.82	$0.81	$1.07	$0.89	$0.97	$1.14
EBITDA	1,857	1,914	2,276	2,193	1,968	1,772	2,589	2,493

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABT vs MDT MDT vs SYK GEHC vs MDT

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Medtronic's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Medtronic.